Targeting ion transport in cancer

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1638, 2014, Pages

  Oosterwijk, E ^a   Gillies, R J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Carbonic anhydrase IX; Clinical experience; Targeting; Translation; Tumour acidity

Indexed keywords

CANCER; CYTOLOGY; DISEASE TREATMENT; ENZYME ACTIVITY; FUNCTIONAL ROLE; ION; MEDICINE; METABOLISM; PATHOLOGY; PH; PHYSIOLOGY; SIGNALING;

CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; TUMOR ANTIGEN;

ACID BASE BALANCE; ACIDOSIS; ANIMAL; ARTICLE; CLINICAL EXPERIENCE; HUMAN; ION TRANSPORT; METABOLISM; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; PH; PHYSIOLOGY; TARGETING; TRANSLATION; TUMOR MICROENVIRONMENT; TUMOUR ACIDITY;

CARBONIC ANHYDRASE IX; CLINICAL EXPERIENCE; TARGETING; TRANSLATION; TUMOUR ACIDITY;

ACID-BASE EQUILIBRIUM; ACIDOSIS; ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; HUMANS; HYDROGEN-ION CONCENTRATION; ION TRANSPORT; MICE; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84893495337     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0107     Document Type: Review

References (81)

1. Gillies RJ, Verduzco D, Gatenby RA. 2012 Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 12, 487-493. (doi:10.1038/nrc3298)
2. Arcangeli A, Yuan JX. 2011 American journal of physiology-cell physiology theme: ion channels and transporters in cancer. Am. J. Physiol. Cell Physiol. 301, C253-C254. (doi:10.1152/ajpcell. 00159.2011)
3. Munaron L, Arcangeli A. 2013 Editorial: ion fluxes and cancer. Recent Patens Anticancer Drug Discov. 8, 1-3. (doi:10.2174/15748928130101)
4. Levin M. 2007 Large-scale biophysics: ion flows and regeneration. Trends Cell Biol. 17, 261-270. (doi:10.1016/j.tcb.2007.04.007)
5. Holder JW, Elmore E, Barrett JC. 1993 Gap junction function and cancer. Cancer Res. 53, 3475-3485.
6. Holzer P. 2011 Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther. 131, 142-170. (doi:10.1016/j.pharmthera.2011.03.006)
7. Parkash J, Asotra K. 2010 Calcium wave signaling in cancer cells. Life Sci. 87, 587-595. (doi:10.1016/j. lfs.2010.09.013)
8. Levin M. 2013 Reprogramming cells and tissue patterning via bioelectrical pathways: molecular mechanisms and biomedical opportunities. Wiley Interdiscip. Rev. Syst. Biol. Med. 5, 657-676. (doi:10.1002/wsbm.1236)
9. Levin M. 2011 The wisdom of the body: future techniques and approaches to morphogenetic fields in regenerative medicine, developmental biology and cancer. Regen. Med. 6, 667-673. (doi:10.2217/rme.11.69)
10. Chakravarti B, Chattopadhyay N, Brown EM. 2012 Signaling through the extracellular calciumsensing receptor (CaSR). Adv. Exp. Med. Biol. 740, 103-142. (doi:10.1007/978-94-007-2888-2_5)
11. Wang YZ, Xu TL. 2011 Acidosis, acid-sensing ion channels, and neuronal cell death. Mol. Neurobiol. 44, 350-358. (doi:10.1007/s12035-011-8204-2)
12. Yingjun G, Xun Q. 2013 Acid-sensing ion channels under hypoxia. Channels 7, 231-237. (doi:10.4161/chan.25223)
13. McGuire J, Herman JP, Ghosal S, Eaton K, Sallee FR, Sah R. 2009 Acid-sensing by the T cell deathassociated gene 8 (TDAG8) receptor cloned from rat brain. Biochem. Biophys. Res. Commun. 386, 420-425. (doi:10.1016/j.bbrc.2009.05.133)
14. Hizaki K et al. 2011 Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis. Mod. Pathol. 24, 876-884. (doi:10.1038/modpathol.2011.10)
15. Tsoulfas G. 2013 Blockade of chloride ion transport enhances the cytocidal effect of hypotonic solution in gastric cancer cells. J. Surg. Res. 179, e49-e50. (doi:10.1016/j.jss.2011.12.040)
16. Friedl P, Brocker EB. 2000 The biology of cell locomotion within three-dimensional extracellular matrix. Cell. Mol. Life Sci. 57, 41-64. (doi:10.1007/s000180050498)
17. Wolf K, Friedl P. 2006 Molecular mechanisms of cancer cell invasion and plasticity. Br. J. Dermatol. 154(Suppl. 1), 11-15. (doi:10.1111/j.1365-2133. 2006.07231.x)
18. Cuddapah VA, Sontheimer H. 2011 Ion channels and transporters [corrected] in cancer. 2. Ion channels and the control of cancer cell migration. Am. J. Physiol. Cell Physiol. 301, C541-C549. (doi:10.1152/ajpcell.00102.2011)
19. Haas BR, Cuddapah VA, Watkins S, Rohn KJ, Dy TE, Sontheimer H. 2011 With-No-Lysine Kinase 3 (WNK3) stimulates glioma invasion by regulating cell volume. Am. J. Physiol. Cell Physiol. 301, C1150-C1160. (doi:10.1152/ajpcell.00203.2011)
20. Haas BR, Sontheimer H. 2010 Inhibition of the sodium-potassium-chloride cotransporter isoform-1 reduces glioma invasion. Cancer Res. 70, 5597-5606. (doi:10.1158/0008-5472.CAN-09-4666)
21. Schwab A, Fabian A, Hanley PJ, Stock C. 2012 Role of ion channels and transporters in cell migration. Physiol. Rev. 92, 1865-1913. (doi:10.1152/physrev. 00018.2011)
22. Robey IF et al. 2009 Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 69, 2260-2268. (doi:10.1158/0008-5472.CAN-07-5575)
23. Seyhan AA, Varadarajan U, Choe S, Liu W, Ryan TE. 2012 A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. Mol. Biosyst. 8, 1553-1570. (doi:10.1039/c2mb05512k)
24. Zhang Y, Li M, Yao Q, Chen C. 2009 Roles and mechanisms of copper transporting ATPases in cancer pathogenesis. Med. Sci. Monit. 15, RA1-RA5.
25. 2+ transport in cancer: close reality or long perspective? Expert Opin. Ther. Targets 17, 225-241. (doi:10.1517/14728222.2013.741594)
26. Madelin G, Regatte RR. 2013 Biomedical applications of sodium MRI in vivo. J. Magn. Reson. Imaging 38, 511-529. (doi:10.1002/jmri.24168)
27. Ouwerkerk R. 2011 Sodium MRI. Methods Mol. Biol. 711, 175-201. (doi:10.1007/978-1-61737-992-5_8)
28. Alvarez-Baron CP, Jonsson P, Thomas C, Dryer SE, Williams C. 2011 The two-pore domain potassium channel KCNK5: induction by estrogen receptor alpha and role in proliferation of breast cancer cells. Mol. Endocrinol. 25, 1326-1336. (doi:10.1210/me. 2011-0045)
29. + channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br. J. Pharmacol. 159, 650-658. (doi:10.1111/j.1476-5381.2009.00557.x)
30. Gillies RJ, Deamer DW. 1979 Intracellular pH changes during the cell cycle in Tetrahymena. J. Cell Physiol. 100, 23-31. (doi:10.1002/jcp.1041000103)
31. Bailey KM, Wojtkowiak JW, Hashim AI, Gillies RJ. 2012 Targeting the metabolic microenvironment of tumors. Adv. Pharmacol. 65, 63-107. (doi:10.1016/B978-0-12-397927-8.00004-X)
32. Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, Gillies RJ. 2011 Imaging pH and metastasis. NMR Biomed. 24, 582-591.
33. Bhujwalla ZM, Artemov D, Aboagye E, Ackerstaff E, Gillies RJ, Natarajan K, Solaiyappan M. 2001 The physiological environment in cancer vascularization, invasion and metastasis. Novartis Found. Symp. 240, 23-38 (discussion 45, 152-153). (doi:10.1002/0470868716.ch3)
34. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. 2006 Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res. 66, 5216-5223. (doi:10.1158/0008-5472.CAN-05-4193)
35. Adams DJ, Morgan LR. 2011 Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development. Curr. Med. Chem. 18, 1367-1372. (doi:10.2174/092986711795029609)
36. Raghunand N et al. 1999 Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer 80, 1005-1011. (doi:10.1038/sj.bjc. 6690455)
37. Raghunand N, Mahoney BP, Gillies RJ. 2003 Tumor acidity, ion trapping and chemotherapeutics. II. pHdependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem. Pharmacol. 66, 1219-1229. (doi:10.1016/S0006-2952(03)00468-4)
38. Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. 2011 Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol. Pharm. 8, 2032-2038. (doi:10.1021/mp200292c)
39. Gillies RJ, Anderson AR, Gatenby RA, Morse DL. 2010 The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin. Radiol. 65, 517-521. (doi:10.1016/j. crad.2010.04.005)
40. Wijesinghe D, Engelman DM, Andreev OA, Reshetnyak YK. 2011 Tuning a polar molecule for selective cytoplasmic delivery by a pH (low) insertion peptide. Biochemistry 50, 10 215-10 222. (doi:10.1021/bi2009773)
41. Moshnikova A, Moshnikova V, Andreev OA, Reshetnyak YK. 2013 Antiproliferative effect of pHLIP-amanitin. Biochemistry 52, 1171-1178. (doi:10.1021/bi301647y)
42. Zhou T, Xiao C, Fan J, Chen S, Shen J, Wu W, Zhou S. 2013 A nanogel of on-site tunable pH-response for efficient anticancer drug delivery. Acta Biomater. 9, 4546-4557. (doi:10.1016/j.actbio.2012.08.017)
43. Sethuraman VA, Lee MC, Bae YH. 2008 A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm. Res. 25, 657-666. (doi:10.1007/s11095-007-9480-4)
44. Barkey NM, Tafreshi NK, Josan JS, De Silva CR, Sill KN, Hruby VJ, Gillies RJ, Morse DL, Vagner J. 2011 Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J. Med. Chem. 54, 8078-8084. (doi:10.1021/jm201226w)
45. Manchun S, Dass CR, Sriamornsak P. 2012 Targeted therapy for cancer using pH-responsive nanocarrier systems. Life Sci. 90, 381-387. (doi:10.1016/j.lfs. 2012.01.008)
46. Paliwal SR, Paliwal R, Pal HC, Saxena AK, Sharma PR, Gupta PN, Agrawal GP, Vyas SP. 2012 Estrogenanchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Mol. Pharm. 9, 176-186. (doi:10.1021/mp200439z)
47. Chen H et al. 2013 Monitoring pH-triggered drug release from radioluminescent nanocapsules with Xray excited optical luminescence. ACS Nano 7, 1178-1187. (doi:10.1021/nn304369m)
48. Yang X, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Matson VZ, Steeber DA, Gong S. 2010 Multifunctional stable and pH-responsive polymer vesicles formed by heterofunctional triblock copolymer for targeted anticancer drug delivery and ultrasensitive MR imaging. ACS Nano 4, 6805-6817. (doi:10.1021/nn101670k)
49. Silva AS, Yunes JA, Gillies RJ, Gatenby RA. 2009 The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 69, 2677-2684. (doi:10.1158/0008-5472.CAN-08-2394)
50. Martin NK, Robey IF, Gaffney EA, Gillies RJ, Gatenby RA, Maini PK. 2012 Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. Br. J. Cancer 106, 1280-1287. (doi:10.1038/bjc.2012.58)
51. Ibrahim-Hashim A, Cornnell HH, Abrahams D, Lloyd M, Bui M, Gillies RJ, Gatenby RA. 2012 Systemic buffers inhibit carcinogenesis in TRAMP mice. J. Urol. 188, 624-631. (doi:10.1016/j.juro. 2012.03.113)
52. Ibrahim Hashim A, Cornnell HH, Coelho Ribeiro Mde L, Abrahams D, Cunningham J, Lloyd M, Martinez GV, Gatenby RA, Gillies RJ. 2011 Reduction of metastasis using a non-volatile buffer. Clin. Exp. Metastasis 28, 841-849. (doi:10.1007/s10585-011-9415-7)
53. Harguindey S, Arranz JL, Wahl ML, Orive G, Reshkin SJ. 2009 Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res. 29, 2127-2136.
54. Tannock IF, Rotin D. 1989 Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49, 4373-4384.
55. Wong P, Kleemann HW, Tannock IF. 2002 Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br. J. Cancer 87, 238-245. (doi:10.1038/sj.bjc.6600424)
56. + exchanger, pH regulation and cancer. Recent Patent Anticancer Drug Discov. 8, 85-99.
57. + exchanger for tumor growth. Cancer Res. 49, 205-211.
58. Tafreshi NK et al. 2012 Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clin. Cancer Res. 18, 207-219. (doi:10.1158/1078-0432. CCR-11-0238)
59. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. 2010 New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 29, 6509-6521. (doi:10.1038/onc.2010.455)
60. Lou Y et al. 2011 Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71, 3364-3376. (doi:10.1158/0008-5472.CAN-10-4261)
61. Pacchiano F, Carta F, McDonald PC, Lou Y, Vullo D, Scozzafava A, Dedhar S, Supuran CT. 2011 Ureidosubstituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 54, 1896-1902. (doi:10.1021/jm101541x)
62. Touisni N, Maresca A, McDonald PC, Lou Y, Scozzafava A, Dedhar S, Winum J-Y, Supuran CT. 2011 Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J. Med. Chem. 54, 8271-8277. (doi:10.1021/jm200983e)
63. Pastorek J et al. 1994 Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9, 2877-2888.
64. Supuran CT. 2008 Development of small molecule carbonic anhydrase IX inhibitors. BJU Int. 101(Suppl. 4), 39-40. (doi:10.1111/j.1464-410X. 2008.07648.x)
65. Dubois L et al. 2011 Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother. Oncol. 99, v424-v431. (doi:10.1016/j.radonc.2011. 05.045)
66. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO. 1986 Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494. (doi:10.1002/ijc.2910380406)
67. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED. 2007 Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 25, 4757-4764. (doi:10.1200/JCO.2007.12.1087)
68. Grabmaier K et al. 2000 Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer 85, 865-870. (doi:10.1002/(SICI)1097-0215(20000315)85:6,865::AIDIJC21.3.0. CO;2-Q)
69. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. 2004 Strict regulation of CAIX(G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene 23, 5624-5631. (doi:10.1038/sj.onc.1207764)
70. Jaakkola P et al. 2001 Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472. (doi:10.1126/science. 1059796)
71. Schofield CJ, Ratcliffe PJ. 2005 Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 338, 617-626. (doi:10.1016/j.bbrc.2005. 08.111)
72. Potter C, Harris AL. 2004 Hypoxia inducible carbonic anhydrase IX, marker of tumor hypoxia, survival pathway and therapy target. Cell Cycle 3, 164-167. (doi:10.4161/cc.3.2.618)
73. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. 2011 Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11, 167. (doi:10.1186/1471-2407-11-167)
74. Gnarra JR et al. 1994 Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90. (doi:10.1038/ng0594-85)
75. Oosterwijk E et al. 1993 Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol. 11, 738-750.
76. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. 2012 Practical theoretic guidance for the design of tumortargeting agents. Methods Enzymol. 503, 255-268. (doi:10.1016/B978-0-12-396962-0.00010-0)
77. Divgi CR et al. 2007 Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 8, 304-310. (doi:10.1016/S1470-2045(07) 70044-X)
78. Divgi CR et al. 2013 Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J. Clin. Oncol. 31, 187-194. (doi:10.1200/JCO.2011. 41.2445)
79. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. 2010 Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur. Urol. 58, 75-83. (doi:10.1016/j. eururo.2010.03.015)
80. Belldegrun ASC, Kloepfer P, Fall B, Bevan P, Störkel S, Wilhelm O, Pantuck AJ. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-results and implications for adjuvant clinical trials. In ASCO Annual Meeting (May 31-June 4, 2013, Chicago, IL), J. Clin. Oncol. 31, 2013 (suppl; abstr 4507).
81. Hoeben BA et al. 2010 PET of hypoxia with 89Zrlabeled cG250-F(ab')2 in head and neck tumors. J. Nucl. Med. 51, 1076-1083. (doi:10.2967/jnumed. 109.073189)